HMN 2025: How Zonisamide might forestall some migraine assaults in youngsters and youths

For youngsters and youths residing with migraine, there could also be a brand new preventive remedy, in response to a preliminary study launched as we speak, February 26, 2025, that will likely be introduced on the American Academy of Neurology’s 77th Annual Meeting happening April 5–9, 2025, in San Diego and on-line. Researchers discovered the drug zonisamide, which has been used to deal with seizures, might scale back migraine days on this age group. This study doesn’t show that zonisamide reduces migraine days; it solely reveals an affiliation.

“Migraine illness is debilitating and may result in youngsters having to overlook faculty and different actions,” stated writer Anisa Kelley, MD, of Northwestern University Feinberg School of Medicine in Chicago. “Currently, there is just one FDA-approved migraine preventative treatment for this age group. Our outcomes are encouraging, exhibiting zonisamide could also be another choice for lowering migraine assaults.”

For the review, researchers reviewed well being data at one establishment. They recognized 256 youngsters and youths who had been recognized with migraine and prescribed preventative zonisamide. Of these members, 28% had difficult-to-treat migraine, which was outlined as having migraine illness unsuccessfully handled with two or extra earlier medicines. Researchers documented the variety of headache days per thirty days for every participant each earlier than and after beginning zonisamide.

They then divided members into three subgroups primarily based on how lengthy they took the treatment earlier than a follow-up go to with a doctor. The first group adopted up within the first month, the second group inside two to 6 months, and the third group after six months.

For all members, the median variety of headache days per thirty days was lowered from 18 to 6 on the first follow-up go to. When evaluating between the teams, the subgroup that adopted up inside two to 6 months had the biggest discount, with a median lower of six headache days per thirty days. Kelley famous that the information advised the drug was only after a minimum of two months of use.

The knowledge additionally advised that the drug was efficient for each these with difficult-to-treat migraine illness and people with out.

“It’s very thrilling that we might have an efficient technique to deal with troublesome migraine illness in youngsters and teenagers. However, it is essential to notice that our study did have limitations,” stated Kelley. “For occasion, our study didn’t examine folks taking the treatment to individuals who didn’t take the treatment. Future research are wanted with {control} teams to verify our outcomes.”